EBS · Emergent BioSolutions Inc.
$4.59
+0.10 (+2.23%)
At close · Aug 14
Market Cap
$235.34M
Shares
51.27M
Emergent BioSolutions Inc. Earnings Call Transcripts
Every quarterly earnings call for Emergent BioSolutions Inc. (EBS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼16.2%
$239.90M
−$87.10M
'22 Q3
22-11-08
▼54.9%
$330.20M
−$67.00M
'22 Q4
23-01-09
▼46.1%
$164.30M
−$186.20M
'23 Q1
23-05-09
▲39.3%
$337.90M
−$261.40M
'23 Q2
23-08-08
▲12.8%
$270.50M
−$263.40M
'23 Q3
23-11-08
▼16.2%
$276.60M
−$49.50M
'23 Q4
24-03-06
▲82.8%
$300.40M
$9.00M
'24 Q1
24-05-01
▼24.6%
$254.70M
−$283.10M
'24 Q2
24-08-06
▲8.6%
$293.80M
$114.80M
'24 Q3
24-10-02
▼29.6%
$194.70M
−$31.30M
'24 Q4
25-03-03
▼26%
$222.20M
$68.00M
'25 Q1
25-05-07
▼44.7%
$140.90M
−$12.00M
'25 Q2
25-08-06
▼21.3%
$231.10M
$51.20M
'25 Q3
25-10-29
▼23.6%
$148.70M
−$54.60M
'25 Q4
26-02-26
▼29.7%
$156.10M
$6.80M
'26 Q1
26-04-30
LATEST
▲66.3%
$234.30M
−$180.20M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Emergent BioSolutions Inc. Earnings Conference Call
Positive tone
Naloxone/Narcan market pressure
MCM / government contracts
International expansion
Revenue
$234.30M
▲ 66.3% YoY Diluted EPS
$-3.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Emergent BioSolutions Inc. Q1 FY2026 Earnings Call
Positive tone
Q1 financial results vs. guidance
Debt reduction and capital allocation
Product acquisitions and pipeline (SAB, Canton)
Revenue
$156.10M
▼ 29.7% YoY Diluted EPS
$0.07
▼ 94.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Emergent BioSolutions Inc. Q4 FY2025 Earnings Call
Confident tone
NARCAN / naloxone market leadership
Financial performance and profitability
Debt reduction and balance sheet
Revenue
$148.70M*
▼ 23.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Emergent BioSolutions Inc. Q3 FY2025 Earnings Call
Confident tone
Biodefense / MCM contract momentum
Government shutdown and macro risk
Financial outperformance and raised guidance
Revenue
$231.10M
▼ 21.3% YoY Diluted EPS
$0.91
▼ 55.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Emergent BioSolutions Inc. Q2 FY2025 Earnings Call
Confident tone
Naloxone / NARCAN franchise
Financial performance and guidance raise
Medical Countermeasures (MCM) and biodefense contracts
Revenue
$140.90M
▼ 44.7% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Emergent BioSolutions Inc. Q1 FY2025 Earnings Call
Positive tone
Financial performance and guidance
International medical countermeasure growth
NARCAN and naloxone market
Revenue
$222.20M
▼ 26% YoY Diluted EPS
$1.19
▲ 600% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Emergent BioSolutions Inc. Q4 FY2024 Earnings Call
Positive tone
Kloxado acquisition and integration
Medical countermeasures (MCM) government contracts
NARCAN nasal spray and opioid response
Revenue
$194.70M*
▼ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-02
Emergent BioSolutions Inc. Q3 FY2024 Earnings Call
Positive tone
Revenue and EBITDA guidance
Multi-year turnaround plan
Operational cost reductions and site network
Revenue
$293.80M
▲ 8.6% YoY Diluted EPS
$2.06
Gross margin
54.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Emergent BioSolutions Inc. Q2 FY2024 Earnings Call
Positive tone
Restructuring and workforce reduction
Manufacturing and margin improvement
NARCAN Nasal Spray growth and access expansion
Revenue
$254.70M
▼ 24.6% YoY Diluted EPS
$-5.38
Gross margin
-18.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Emergent BioSolutions Inc. Q1 FY2024 Earnings Call
Positive tone
NARCAN
Medical countermeasures (MCM)
Guidance raise
Revenue
$300.40M
▲ 82.8% YoY Diluted EPS
$0.17
Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Emergent BioSolutions Inc. Q4 FY2023 Earnings Call
Cautious tone
MCM / government procurement
NARCAN Nasal Spray / opioid crisis
New CEO transition
Revenue
$276.60M*
▼ 16.2% YoY Gross margin
30.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Emergent BioSolutions Inc. Q3 FY2023 Earnings Call
Revenue
$270.50M
▲ 12.8% YoY Diluted EPS
$-5.08
Gross margin
32.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Emergent BioSolutions Inc. Q2 FY2023 Earnings Call
Revenue
$337.90M
▲ 39.3% YoY Diluted EPS
$-5.16
Gross margin
41.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Emergent BioSolutions Inc. Q1 FY2023 Earnings Call
Revenue
$164.30M
▼ 46.1% YoY Diluted EPS
$-3.71
Gross margin
3.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Emergent BioSolutions Inc. Q4 FY2022 Earnings Call
Revenue
$330.20M
▼ 54.9% YoY Diluted EPS
$-1.34
▼ 137.2% YoY Gross margin
30.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Emergent BioSolutions Inc. Q3 FY2022 Earnings Call
Revenue
$239.90M
▼ 16.2% YoY Diluted EPS
$-1.75
Gross margin
31.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-01
Emergent BioSolutions Inc. Q2 FY2022 Earnings Call
Revenue
$242.60M
▼ 35.7% YoY Diluted EPS
$-1.06
Gross margin
27.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Emergent BioSolutions Inc. Q1 FY2022 Earnings Call
Revenue
$304.80M
▼ 19.2% YoY Diluted EPS
$-0.09
▼ 107.3% YoY Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Emergent BioSolutions Inc. Q4 FY2021 Earnings Call
Revenue
$732.90M
▲ 25.7% YoY Diluted EPS
$3.60
▲ 4.7% YoY Gross margin
58.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Emergent BioSolutions Inc. Q3 FY2021 Earnings Call
Revenue
$286.30M
▼ 25.7% YoY Diluted EPS
$-0.75
▼ 202.7% YoY Gross margin
33.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Emergent BioSolutions Inc. Q2 FY2021 Earnings Call
Revenue
$377.40M
▼ 4.4% YoY Diluted EPS
$-0.01
▼ 100.6% YoY Gross margin
38.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Emergent BioSolutions Inc. Q1 FY2021 Earnings Call
Revenue
$377.00M
▲ 95.8% YoY Diluted EPS
$1.23
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Emergent BioSolutions Inc. Q4 FY2020 Earnings Call
Revenue
$583.00M
▲ 61.8% YoY Diluted EPS
$3.44
▲ 282.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Emergent BioSolutions Inc. Q3 FY2020 Earnings Call
Revenue
$385.20M
▲ 23.5% YoY Diluted EPS
$0.73
▼ 12% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Emergent BioSolutions Inc. Q2 FY2020 Earnings Call
Revenue
$394.70M
▲ 62.3% YoY Diluted EPS
$1.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Emergent BioSolutions Inc. Q1 FY2020 Earnings Call
Revenue
$192.50M
▲ 1% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Emergent BioSolutions Inc. Q4 FY2019 Earnings Call
Revenue
$360.40M
▲ 33.1% YoY Diluted EPS
$0.90
Gross margin
21.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY19 · Q3
2019-11-06
Emergent BioSolutions Inc. Q3 FY2019 Earnings Call
Revenue
$311.80M
▲ 79.5% YoY Diluted EPS
$0.83
▲ 102.4% YoY Gross margin
22.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q2
2019-08-01
Emergent BioSolutions Inc. Q2 FY2019 Earnings Call
Revenue
$243.20M
▲ 10.4% YoY Diluted EPS
$-0.18
▼ 118.4% YoY Gross margin
-2.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q1
2019-05-02
Emergent BioSolutions Inc. Q1 FY2019 Earnings Call
Revenue
$190.60M
▲ 61.8% YoY Diluted EPS
$-0.51
Gross margin
-14.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q4
2019-02-21
Emergent BioSolutions Inc. Q4 FY2018 Earnings Call
Revenue
$270.70M
▲ 39.7% YoY Diluted EPS
$-0.07
Gross margin
4.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY18 · Q3
2018-11-01
Emergent BioSolutions Inc. Q3 FY2018 Earnings Call
Revenue
$173.70M
▲ 16.3% YoY Diluted EPS
$0.41
▼ 39.7% YoY Gross margin
12.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q2
2018-08-02
Emergent BioSolutions Inc. Q2 FY2018 Earnings Call
Revenue
$220.20M
▲ 118.5% YoY Diluted EPS
$0.98
▲ 790.9% YoY Gross margin
30.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q1
2018-05-03
Emergent BioSolutions Inc. Q1 FY2018 Earnings Call
Revenue
$117.80M
▲ 0.8% YoY Diluted EPS
$-0.10
▼ 143.5% YoY Gross margin
-8.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q4
2018-02-22
Emergent BioSolutions Inc. Q4 FY2017 Earnings Call
Revenue
$193.80M
▲ 27.8% YoY Gross margin
27.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY17 · Q3
2017-11-02
Emergent BioSolutions Inc. Q3 FY2017 Earnings Call
Revenue
$149.40M
▲ 4.5% YoY Diluted EPS
$0.68
▲ 51.1% YoY Gross margin
32.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q2
2017-08-03
Emergent BioSolutions Inc. Q2 FY2017 Earnings Call
Revenue
$100.80M
▲ 10.5% YoY Diluted EPS
$0.11
Gross margin
8.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q1
2017-05-04
Emergent BioSolutions Inc. Q1 FY2017 Earnings Call
Revenue
$116.90M
▲ 5.3% YoY Diluted EPS
$0.23
▲ 130% YoY Gross margin
12.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q4
2017-02-23
Emergent BioSolutions Inc. Q4 FY2016 Earnings Call
Revenue
$151.66M
▼ 5.1% YoY Diluted EPS
$0.77
▲ 8.5% YoY Gross margin
33.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY16 · Q3
2016-11-07
Emergent BioSolutions Inc. Q3 FY2016 Earnings Call
Revenue
$142.91M
▼ 13.4% YoY Diluted EPS
$0.45
▼ 43% YoY Gross margin
24.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q2
2016-06-30
Emergent BioSolutions Inc. Q2 FY2016 Earnings Call
Revenue
$91.24M
▼ 27.7% YoY Diluted EPS
$-0.27
▼ 184.4% YoY Gross margin
-2.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q1
2016-05-05
Emergent BioSolutions Inc. Q1 FY2016 Earnings Call
Revenue
$111.00M
▲ 74.4% YoY Diluted EPS
$0.10
Gross margin
19.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q4
2016-02-25
Emergent BioSolutions Inc. Q4 FY2015 Earnings Call
Revenue
$159.78M
▲ 8% YoY Diluted EPS
$0.71
▲ 7.6% YoY Gross margin
40.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY15 · Q3
2015-11-05
Emergent BioSolutions Inc. Q3 FY2015 Earnings Call
Revenue
$164.94M
▲ 19.6% YoY Diluted EPS
$0.79
▲ 61.2% YoY Gross margin
38.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q2
2015-08-06
Emergent BioSolutions Inc. Q2 FY2015 Earnings Call
Revenue
$126.11M
▲ 14.3% YoY Diluted EPS
$0.32
▲ 146.2% YoY Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q1
2015-05-07
Emergent BioSolutions Inc. Q1 FY2015 Earnings Call
Revenue
$63.63M
▲ 18.1% YoY Diluted EPS
$-0.57
Gross margin
-34.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY14 · Q4
2015-03-05
Emergent BioSolutions Inc. Q4 FY2014 Earnings Call
Revenue
$147.97M
▲ 50.8% YoY Diluted EPS
$0.66
▲ 61% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY14 · Q3
2014-11-06
Emergent BioSolutions Inc. Q3 FY2014 Earnings Call
Revenue
$137.95M
▲ 54.8% YoY Diluted EPS
$0.49
▲ 36.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY14 · Q2
2014-08-07
Emergent BioSolutions Inc. Q2 FY2014 Earnings Call
Revenue
$110.33M
▲ 33.8% YoY Diluted EPS
$0.13
▼ 55.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY14 · Q1
2014-05-08
Emergent BioSolutions Inc. Q1 FY2014 Earnings Call
Revenue
$53.88M
▲ 25% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–50 of 78 earnings calls
Key facts
CIK
1367644
CUSIP
29089Q105
13F (30d)
190 filings
187 filers
Visit website
Investor relations